Every peptide I've covered in this pillar so far has occupied some version of "promising mechanism, evidence still developing." I've tried to extend real, honest consideration to each one, while being precise about exactly how strong or thin that evidence actually is. This post is different, deliberately. DSIP — known in regulatory contexts by its official name, emideltide — was the one peptide out of seven reviewed at the same FDA compounding committee meeting I've referenced throughout this pillar that the committee actually declined to recommend. I think it's worth understanding exactly why, because the reasoning is more instructive than a simple pass/fail.
What DSIP actually is
Delta sleep-inducing peptide is a nine-amino-acid peptide first isolated in 1974 from research involving induced sleep in rabbits. It's naturally present in the human hypothalamus, limbic system, and pituitary gland, and researchers have proposed it plays some role in slow-wave sleep and stress regulation. I want to be direct about something here that distinguishes this peptide from most others I've covered: its actual mechanism has never been clearly established. It appears to interact with stress-response signaling and possibly glucocorticoid-related pathways, but which specific receptors it acts through, and how, remains genuinely unclear even after five decades of intermittent study.
The vote, and why the margin matters
In July 2026, the same committee that reviewed BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon — recommending all six for the compounding pathway — voted against recommending DSIP, by a narrow margin reported as split almost evenly with one abstention. It's worth sitting with how close that vote actually was, because it means this wasn't an obvious, unanimous rejection. It was a genuine, contested judgment call, decided by essentially a single vote.
What makes this instructive is the reasoning panelists gave for voting no, which I think deserves to be laid out plainly rather than summarized as "they didn't like it." Panelists cited low-quality efficacy evidence, poor characterization of the substance itself — meaning real uncertainty about its chemical identity, purity, and consistency across preparations — and the existence of already-approved therapies for the conditions DSIP is marketed toward, including insomnia, narcolepsy, and opioid withdrawal support. One panelist specifically noted he couldn't disregard the FDA's own staff safety concerns, which had recommended against all seven peptides reviewed that day, DSIP included.
The evidence itself, and why "insufficient" undersells it
Here's the detail I think matters most, and it's genuinely different from anything else covered in this pillar. For most peptides I've discussed — BPC-157, KPV, and others — the honest description of the evidence gap is that rigorous human trials simply haven't been done yet. That's not quite true for DSIP. Two placebo-controlled human trials, conducted in the 1990s, specifically tested whether DSIP improved sleep. Neither found it outperformed placebo.
I want to be precise about what that means, because it's a meaningfully different category of finding than "we don't know yet." This isn't an absence of evidence — it's evidence that, where it does exist, has pointed against the primary effect DSIP is marketed for. That doesn't mean every possible use of DSIP has been definitively disproven; the trials were small, decades old, and didn't address every proposed application, including opioid withdrawal support. But it does mean the honest evidence-tier placement for DSIP's core sleep claim isn't "Tier 3, promising but unproven." It's closer to "tested directly, and the direct test didn't support it."
The direct comparison worth naming
Epitalon and DSIP were reviewed in the same batch, marketed toward overlapping claims around sleep, and landed in opposite places — one recommended, one not. I think that contrast is worth sitting with directly, because it's a clean illustration of why I've tried throughout this pillar to evaluate each peptide on its own specific evidence, rather than treating "peptide reviewed by this committee" as a single category with a single answer. Two compounds, similar marketing, genuinely different evidence, genuinely different outcomes.
What I'd want you to take from this
I've spent this entire pillar arguing that mechanistic plausibility and thin-but-real evidence deserve honest, careful consideration rather than dismissal — that's the whole premise behind the evidence framework this pillar is built on. DSIP is the case that shows the other side of that same honesty. Sometimes the evidence that exists doesn't support the claim being made, a committee of experts looks at exactly that evidence and says so by the narrowest possible margin, and the honest thing to do is report that clearly rather than rounding it up to "still promising" out of habit. Extending fair consideration to emerging peptides doesn't mean every peptide clears the bar. This one, on the evidence currently available, didn't.
Curious how to evaluate a peptide's real evidence base before considering it?
No spam. Occasional new posts and updates from The Center for Metabolic Health.
Medical disclaimer: This content is provided for general educational and informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any condition, and it does not create a physician-patient relationship. Every patient's medical history, health status, and treatment needs are different. Always consult your own physician or qualified healthcare provider before starting, stopping, or changing any medication or treatment, and before making any decisions based on information found here. If you are experiencing a medical emergency, call 911 or go to your nearest emergency room.